留言板

尊敬的读者、作者、审稿人, 关于本刊的投稿、审稿、编辑和出版的任何问题, 您可以本页添加留言。我们将尽快给您答复。谢谢您的支持!

姓名
邮箱
手机号码
标题
留言内容
验证码

应中央军委要求,2022年9月起,《药学实践杂志》将更名为《药学实践与服务》,双月刊,正文96页;2023年1月起,拟出版月刊,正文64页,数据库收录情况与原《药学实践杂志》相同。欢迎作者踊跃投稿!

真核延长因子eEF1A功能研究进展

程君 芮耀诚

程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
引用本文: 程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
Citation: CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003

真核延长因子eEF1A功能研究进展

doi: 10.3969/j.issn.1006-0111.2012.02.003

Advance in function of the eukaryotic elongation factor eEF1A

  • 摘要: 真核延长因子(eEFs)是一类在蛋白质合成过程中发挥肽链延伸作用的重要分子,在真核生物体内它有eEF1和eEF2两个亚型。其中在肽链延伸过程中起主要作用的eEF1A 是eEF1的一个亚型,它不但能促进氨酰基-tRNA(aa-tRNA)与核糖体的A位点结合,发挥肽链延伸功能;而且近年来大量的研究表明它在细胞凋亡、肿瘤的发生、细胞内信号转导及心血管系统的调节方面均发挥了重要作用,而且这些作用与它在蛋白合成中的功能无关;这表明eEF1A是一个多功能蛋白,能够成为一个潜在的疾病防治的靶点。本文就国内外近几年来有关eEF1A的研究做一综述,介绍真核延长因子eEF1A功能研究的进展。
  • [1] Lamberti A,araglia M,longo O,et al.The translation elongation factor 1A in tumorigenesis, signal transduction and apoptosis[J]. Amino Acids,2004,26(4):443.
    [2] Infante C,sensio E,aavate JP,et al. Molecular characterization and expression analysis of five different elongation factor 1 alpha genes in the flatfish Senegalese sole (Solea senegalensis Kaup): Differential gene expression and thyroid hormones dependence during metamorphosis[J]. BMC Mol Biol,2008,9:19.
    [3] Maria K,Mateyak,Kinzy TG. eEF1A: Thinking outside the ribosome[J]. J Biol Chem,2010,5(4):432.
    [4] Ejiri Shin ichiro. Moonlighting functions of polypeptide elongation factor 1:from actin bundling to zinc finger protein r1-associated nuclear localization[J]. Biotechnol Biochem,2002,66(1):1.
    [5] Khalyfa A,Bourbeau D,Chen E,et al. Characterization of Elongation Factor-1A (eEF1A-1) and eEF1A-2/S1 Protein Expression in Normal and wasted Mice[J]. J Biol Chem,2001,276(25):22915.
    [6] Newbery HJ,Loh DH,Donoghue JE,et al. Translation elongation factor eEF1A2 is essential for post-weaning survival in mice[J]. J Biol Chem,2007,282(39):28951.
    [7] Pan J,Ruest LB,Xu SY,et al. Immuno-characterization of the switch of peptide elongation factors eEF1A-1/EF-1a and eEF1A-2/S1 in the central nervous system during mouse development[J]. Dev Brain Res,2004,149:1.
    [8] Andersen GR,Nissen P,Nyborg J. Elongation factors in protein biosynthesis[J]. Trends Biochem Sci,2003,28(8):434.
    [9] Villa E,Sengupta J,Trabuco LG,et al. Ribosome-induced changes in elongation factor Tu conformation control GTP hydrolysis[J]. Proc Natl Acad Sci,2009,106(4):1063.
    [10] Ruest LB,Marcotte R,Wang E. Peptide elongation factor eEF1A-2/S1 expression in cultured differentiated myotubes and its protective effect against caspase3-mediated apoptosis[J]. J Biol Chem,2002,277(7):5418.
    [11] Borradaile NM, Buhman KK, Listenberger LL, et al. A critical role for eukaryotic elongation factor 1A1 in lipotoxic cell death[J]. Mol Biol Cell,2006,17:770.
    [12] Talapatra1 S,Wagner J,Thompson CB. Elongation factor-1 alpha is a selective regulator of growth factor withdrawal and ER stress-induced apoptosis[J]. Cell Death and Differ, 2002,9:856.
    [13] Li HT,Su YP,Cheng TM,et al. The interaction between interferon-induced protein with tetratricopeptide repeats-1 and eukaryotic elongation factor-1A[J]. Mol Cell Biochem,2010, 337:101.
    [14] Mansillaa F,Hansenb LL,Jakobsena H,et al. Deconstructing PTI-1: PT1-1 is a truncated, but not mutated form of translation elongation factor 1A1, eEF1A1[J]. Biochim Biophys Acta,2005,1727(2):116.
    [15] Zhang JP,Guo HT,Mi ZY,et al. EF1A1-actin interactions alter mRNA stability to determine differential osteopontin expression in HepG2 and Hep3B cells[J]. Exp Cell Res,2009,315:304.
    [16] Anand N,Urthy S,Mann G,et al.Protein elongation factor eEF1A2 is a putative oncogene in ovarian cancer[J]. Nat Genet,2002,31:301.
    [17] Tomlinson VA,ewbery HJ,ray NR,et al. Translation elongation factor eEF1A2 is a potential oncoprotein that is overexpressed in two-thirds of breast tumours[J]. BMC cancer,2005,5:113.
    [18] Morikawa E,Moskowitz M,Huang Z,et al. L-Arginine infusion promotes nitric oxide dependent vasodilation,increases regional blood flow and reduces infarct volume in the rat[J]. Stroke,1994,25(2):429.
    [19] Yan GJ,You B,Chen SP,et al. Tumor necrosis factor-a downregulates endothelial nitric oxide synthase mRNA stability via translation elongation factor 1A1[J]. Circ Res,2008,103(12):591.
    [20] Picchi A,Gao X,Belmadani S. Tumor necrosis factor-alpha induces endothelial dysfunction in the prediabetic metabolic syndrome[J]. Circ Res,2006,99:69.
    [21] Agnoletti L,Curello S,Bachetti T,et al. Serum from patients with severe heart failure downregulates eNOS and is proapoptotic:role of tumor necrosis factor-alpha[J]. Circulation, 1999,100:1983.
    [22] Gross SR,Kinzy TG. Tranlation elongation factor 1A is essential for regulation of actin cytoskeleton and cell morphology[J]. Nat Struct Mol Boil,2005,12:772.
    [23] Leclercq TM, Moretti PAB, Vadas MA, et al.Eukaryotic elongation factor 1A interacts with sphingosine kinase and directly enhances its catalytic activity[J]. J Biol Chem,2008,283:9606.
    [24] Gillardon F. Interaction of elongation factor 1-a with leucine-rich repeat kinase 2 impairs kinase activity and microtubule bundling in vitro[J]. Neuroscience,2009,163:533.
    [25] Yuka Hotokezaka,Udo Tobben,Hitoshi Hotokezaka,et al. Interaction of the Eukaryotic Elongation Factor 1A with NewlySynthesized Polypeptides[J]. J Biol Chem,2002,277(21):18545.
    [26] Shamovsky Iiya,Ivannikov Maxim,Kandel ES,et al. RNA-mediated response to heart shock in mammalian cells[J]. Nature,2006,440(23):556.
  • [1] 毛智毅, 王筱燕, 陈晓颖, 汤逸斐.  度拉糖肽联合二甲双胍对肥胖型2型糖尿病患者机体代谢、体脂成分及血清脂肪因子的影响 . 药学实践与服务, 2024, 42(7): 305-309. doi: 10.12206/j.issn.2097-2024.202305032
    [2] 崔晓林, 付晓菲, 杜艳红, 刘娟, 朱茜, 刘子祺.  临床药师参与吉瑞替尼致QTc间期延长的病例分析 . 药学实践与服务, 2024, 42(6): 263-266. doi: 10.12206/j.issn.2097-2024.202309050
    [3] 刘丽艳, 余小翠, 孙传铎.  纳武利尤单抗治疗非小细胞肺癌有效性及安全性的Meta分析 . 药学实践与服务, 2024, 42(): 1-6. doi: 10.12206/j.issn.2097-2024.202310044
    [4] 宋雨桐, 夏德润, 顾珩, 唐少文, 易洪刚, 沃红梅.  帕博利珠单抗与铂类化疗方案在晚期非小细胞肺癌一线治疗中的药物经济学评价 . 药学实践与服务, 2024, 42(7): 1-7. doi: 10.12206/j.issn.2097-2024.202303023
    [5] 姜涛, 徐卫凡, 蒋益萍, 夏天爽, 辛海量.  巴戟天丸组方对Aβ损伤成骨细胞的作用及基于网络药理学的机制研究 . 药学实践与服务, 2024, 42(7): 285-290, 296. doi: 10.12206/j.issn.2097-2024.202305011
    [6] 修建平, 杨朝爱, 刘禧澳, 潘乾禹, 韦广旭, 王卫星.  全反式维甲酸对肝星状细胞活化及氧化应激的作用和机制探索 . 药学实践与服务, 2024, 42(7): 1-6. doi: 10.12206/j.issn.2097-2024.202312054
    [7] 杨媛媛, 安晓强, 许佳捷, 江键, 梁媛媛.  正极性驻极体联合5-氟尿嘧啶对瘢痕成纤维细胞生长抑制的协同作用 . 药学实践与服务, 2024, 42(6): 244-247. doi: 10.12206/j.issn.2097-2024.202310027
    [8] 冯志惠, 邓仪卿, 叶冰, 安培, 张宏, 张海军.  雀梅藤石油醚提取物诱导三阴性乳腺癌细胞凋亡的实验研究 . 药学实践与服务, 2024, 42(6): 253-259. doi: 10.12206/j.issn.2097-2024.202311055
  • 加载中
计量
  • 文章访问数:  3581
  • HTML全文浏览量:  405
  • PDF下载量:  379
  • 被引次数: 0
出版历程
  • 收稿日期:  2011-07-14
  • 修回日期:  2011-12-05

真核延长因子eEF1A功能研究进展

doi: 10.3969/j.issn.1006-0111.2012.02.003

摘要: 真核延长因子(eEFs)是一类在蛋白质合成过程中发挥肽链延伸作用的重要分子,在真核生物体内它有eEF1和eEF2两个亚型。其中在肽链延伸过程中起主要作用的eEF1A 是eEF1的一个亚型,它不但能促进氨酰基-tRNA(aa-tRNA)与核糖体的A位点结合,发挥肽链延伸功能;而且近年来大量的研究表明它在细胞凋亡、肿瘤的发生、细胞内信号转导及心血管系统的调节方面均发挥了重要作用,而且这些作用与它在蛋白合成中的功能无关;这表明eEF1A是一个多功能蛋白,能够成为一个潜在的疾病防治的靶点。本文就国内外近几年来有关eEF1A的研究做一综述,介绍真核延长因子eEF1A功能研究的进展。

English Abstract

程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
引用本文: 程君, 芮耀诚. 真核延长因子eEF1A功能研究进展[J]. 药学实践与服务, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
Citation: CHENG Jun, RUI Yao-cheng. Advance in function of the eukaryotic elongation factor eEF1A[J]. Journal of Pharmaceutical Practice and Service, 2012, 30(2): 89-91,124. doi: 10.3969/j.issn.1006-0111.2012.02.003
参考文献 (26)

目录

    /

    返回文章
    返回